SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
On May 14, 2022, Peter Fromen, the Chief Commercial Officer of Pacific Biosciences of California, Inc. (the “Company”), notified the Company of his intention to resign, effective as of May 20, 2022, to pursue new opportunities. Mr. Fromen’s decision to resign did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
The Company is conducting a search for its next Chief Commercial Officer. Until a successor is appointed, Christian Henry, Chief Executive Officer and President, will take over the Company’s marketing responsibilities, and Chris Seipert, Vice President, Customer Experience, and formerly the Company’s Vice President & General Manager – The Americas & EMEA, will take over the Company’s sales, service and support responsibilities.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Pacific Biosciences of California, Inc.|
|By:||/s/ Brett Atkins|
|Date: May 17, 2022|